Facebook Twitter LinkedIn Google Plus RSS

Derma Sciences announces public offering worth up to $86M

By ,

Princeton-based tissue regeneration company Derma Sciences announced Friday it has priced its public offering of 6.52 million shares of common stock at $11.50 per share.

According to the announcement, the company has granted the underwriters a 30-day option to purchase an additional 978,261 shares to cover any potential over-allotments, if any. The offering is expected to close Tuesday. Piper Jaffray & Co. and Canaccord Genuity Inc. are acting as joint bookrunning managers for the offering. Oppenheimer & Co. Inc. and Roth Capital Partners are acting as financial advisors to the Company.

Gross proceeds from the sale of the shares of common stock are expected to be approximately $75 million, or $86 million if the underwriters exercise their option to purchase additional shares in full. Derma expects to use the proceeds from the offering for the continued development of the wound-healing drug DSC127, for sales forces expansion, and for general corporate purposes, the company said in a statement.

Submit a nomination for General Counsel of the Year >

You May Have Missed...

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy


Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!